News | January 04, 2022
Domestic and emerging markets will drive pharma growth: ICRA
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The product is expected to be available in a week’s time
The drug will be marketed under the brand name Molnaflu
This product will be manufactured at Lupin's Goa facility in India
The capsules are the generic version of the reference listed drug Mycobutin
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
The tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.
Gland Pharma believes that they are amongst one of the first to file for this product and may be eligible for 180 days of generic drug exclusivity
Subscribe To Our Newsletter & Stay Updated
